Zielgerichtete Therapien in der Behandlung des
                    Mammakarzinoms

Jörg B. Engel; Olaf Ortmann

doi:10.1055/s-0033-1346688

Frauenheilkunde up2date, Table of Contents

Frauenheilkunde up2date 2013; 7(5): 363-373
DOI: 10.1055/s-0033-1346688

Allgemeine Gynäkologie und gynäkologische Onkologie

Georg Thieme Verlag KG Stuttgart · New York

Zielgerichtete Therapien in der Behandlung des Mammakarzinoms

Authors

Jörg B. Engel
Olaf Ortmann

Abstract

All articles of this category

Full Text

References

Literatur
1 Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640
2 Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncology 2012; 13: 25-32
3 Ismael G, Hegg R, Muehlbauer S et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncology 2012; 13: 869-878
4 Pivot X, Romieu G, Bonnefoi H et al. PHARE trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. ESMO-Congress 2012; Abstract LBA5: presented October 1; 2012.
5 Gelber RD, Goldhirsch A, Piccart M et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. ESMO Congress 2012; Abstract LBA6: presented October 1; 2012.
6 Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
7 Blackwell KL, Burstein HJ, Storniolo AM et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012; 30: 2585-2592
8 Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791
9 Neven P, Joenssu H, Osborne K et al. Tamoxifen therapy for patients with breast cancer. Lancet 2013; 381: 2078
10 Ingle JN, Tu D, Pater JL et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008; 19: 877-882
11 Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816
12 Beaver JA, Park BH. The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer. Future Oncol 2012; 8: 651-657
13 Finn R. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (BC). Publication Number S1-6 2012 San Antonio Breast Cancer Symposium (SABCS). Texas: San Antonio; 2012
14 OʼShaughnessy J, Romieu G, Dieras V et al. Meta-Analysis of patients with triple-negative breast cancer (TNBC) from three randomized trials of first-line Bevacizumab (BV) and chemotherapy treatment for metastatic breast cancer (MBC). Cancer Res 2010; 70: 452s
15 Von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309
16 Rastogi P, Buyse ME, Swain SM et al. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. Clin Breast Cancer 2011; 11: 228-234
17 OʼShaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-214
18 Buchholz S, Seitz S, Schally AV et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 2009; 35: 789-796
19 Fost C, Duwe F, Hellriegel M et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor. Oncology Reports 2011; 25: 1481-1487
20 Engel JB, Schally AV, Dietl J et al. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharmaceutics 2007; 4: 652-658
21 Engel J, Emons G, Pinski J et al. AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opinion on Investigational Drugs 2012; 21: 891-899
22 Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nature Clin Pract Endocrinol Metabol 2007; 3: 157-167
23 Engel JB, Schally AV, Buchholz S et al. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH). Arch Gynecol Obstet 2012; 286: 437-442
24 Hüttner N, Loehberg CR, Lux MP, Beckmann MW. Onkologische Therapien und Haarverlust. Geburtsh Frauenheilk 2012; 72: R47-R62